Withdrawn from the market (safety)
Lorcaserin
BELVIQ
What it isSelective 5-HT2C agonist; obesity. Withdrawn.
Why this oneIts 5-HT2C selectivity was designed to avoid the 5-HT2B valvulopathy of fenfluramine, and it did.
What limits itIt was withdrawn for a cancer signal in long-term follow-up — a different harm from the one it was engineered to avoid.
FDA-approved for
- obesity (2012 — withdrawn 2020 for cancer signal)
NO BOXED WARNINGS
Principal riskWithdrawn for a cancer signal
Classes and tags
Clinical profile
Mechanism of action: Lorcaserin ballicule
